Unity Biotechnology, Inc.
3280 Bayshore Blvd, Suite 100
Brisbane, California 94005
June 4, 2019
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
| Attention: | Sonia Bednarowski |
| Re: | Unity Biotechnology, Inc. |
| Registration Statement on Form S-3 (Registration No. 333-231893) |
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration by the Securities and Exchange Commission (the “Commission”) of the effective date of the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) of Unity Biotechnology, Inc. (the “Company”). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on June 6, 2019, or as soon as practicable thereafter.
Thank you for your assistance in this matter.
| Very truly yours, | ||
| Unity Biotechnology, Inc. | ||
| By: | /s/ Robert C. Goeltz II | |
| Robert C. Goeltz II | ||
| Chief Financial Officer | ||
| CC: | Keith R. Leonard, Unity Biotechnology, Inc. |
| Tamara L. Tompkins, Unity Biotechnology, Inc. |
| Brian J. Cuneo, Latham & Watkins LLP |
| Miles P. Jennings, Latham & Watkins LLP |